Corvus Pharmaceuticals, Inc. (CRVS) stock
CRVSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$10.17−0.43 (-4.06%)
Close on Nov 17, 2026Market cap $855.51MP/E –Yield –
Corvus Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Corvus Pharmaceuticals's pe ratio was 30.0× on Jan 31, 2022.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2022 | Jan 31, 2022 | 30.0× | −10.2 |
| 2021 | Dec 31, 2021 | 40.2× | – |
See a number that looks wrong?